Exelixis EXEL Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's additional paid-in capital?
- Exelixis (EXEL) reported additional paid-in capital of $2.15B in Q1 2026.
- How has Exelixis's additional paid-in capital changed year-over-year?
- Exelixis's additional paid-in capital decreased by 6.1% year-over-year, from $2.29B to $2.15B.
- What is the long-term trend for Exelixis's additional paid-in capital?
- Over 5 years (2020 to 2025), Exelixis's additional paid-in capital has grown at a -0.8% compound annual growth rate (CAGR), from $2.32B to $2.23B.
- What does additional paid-in capital mean?
- The amount of money shareholders paid for stock above the nominal par value.
- How do you interpret additional paid-in capital?
- An increase indicates successful capital raising or significant employee stock option exercises, reflecting investor confidence or compensation activity.
- How does additional paid-in capital compare across companies?
- High in growth-stage biotech companies that frequently issue equity to fund R&D and clinical trials.